---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-010935"
form_type: "8-K"
ticker: "DRIO"
cik: "0001533998"
company_name: "DarioHealth Corp."
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-20T00:02:47.629658+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# DarioHealth Reports Preliminary FY2022 Revenue of $27.5M and Begins Loan Repayment

## Summary
- Preliminary full-year 2022 total revenue expected $27.5M, up from $20.5M in 2021.
- B2B channel grew to about 60% of revenue in 2022 versus 4% in 2021.
- Operating loss reduced by more than 50% compared to Q4 2021.
- Credit agreement with OrbiMed triggers monthly repayments of up to $518,500 starting January 2023.
- Cash and equivalents at end of 2022: $49.3 million.

## SEC filing metadata
- accession: 0001104659-23-010935
- form_type: 8-K
- ticker: DRIO
- cik: 0001533998
- company_name: DarioHealth Corp.
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.04, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533998/000110465923010935/0001104659-23-010935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533998/000110465923010935/tm235559d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-010935
- JSON: https://secwatch.observer/filing/0001104659-23-010935.json
- Plain text: https://secwatch.observer/filing/0001104659-23-010935.txt

## Key facts
- Debt Financings
  DarioHealth Corp. faced acceleration on credit facility of $25 million with OrbiMed Royalty and Credit Opportunities III, LP maturing June 9, 2027.
  - Instrument: credit facility
  - Principal: $25 million
  - Counterparty: OrbiMed Royalty and Credit Opportunities III, LP
  - Maturity: June 9, 2027
  - Event: acceleration
  source text: the Company started repayment of the outstanding principal amount of the initial tranche of $25 million issued as part of the Loan Facility, together with a repayment premium and other fees in monthly installments of up to $518,500 beginning as of January 31, 2023, and continuing through the maturity date, or June 9, 2027.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533998/000110465923010935/0001104659-23-010935-index.htm
- Earnings Releases
  DarioHealth Corp. reported the fiscal year ended December 31, 2022 results: revenue approximately $27.5 million.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: approximately $27.5 million
  - Result: preliminary results
  source text: DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, today announced preliminary unaudited revenue results for the fourth quarter and full year 2022 of approximately $6.7 million and approximately $27.5 million, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533998/000110465923010935/0001104659-23-010935-index.htm
- Earnings Releases
  DarioHealth Corp. reported the fourth quarter ended December 31, 2022 results: revenue approximately $6.7 million.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: approximately $6.7 million
  - Result: preliminary results
  source text: DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, today announced preliminary unaudited revenue results for the fourth quarter and full year 2022 of approximately $6.7 million and approximately $27.5 million, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533998/000110465923010935/0001104659-23-010935-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.